What's Happening?
Abbisko Therapeutics has announced positive preliminary efficacy results from its Phase II clinical study of lavengratinib (ABSK061), an orally available small-molecule FGFR2/3 inhibitor, for children with achondroplasia (ACH). In the initial and lowest
dose cohort (0.064mg/kg QD), children aged 6 years and older who received lavengratinib for 27 weeks showed a mean increase of +2.4 cm/year in annualized height velocity (AHV) from baseline, with a 100% responder rate. The drug was well-tolerated, with no observed FGFR1 or FGFR2-associated adverse events. Lavengratinib is a novel, highly potent, and selective inhibitor of FGFR2 and FGFR3, independently discovered by Abbisko Therapeutics. It is the first FGFR2/3 inhibitor to enter clinical trials globally and has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). The Phase II study, ABSK061-202, is a multicenter, open-label, dose-escalation study evaluating the safety and efficacy of lavengratinib in children aged 3 to 12 years with ACH, with a planned treatment duration of 78 weeks. The preliminary safety evaluation of the first three dose cohorts has been successfully completed without identified safety concerns.
Why It's Important?
The positive preliminary results for lavengratinib are significant for the achondroplasia community, particularly in the U.S., as it offers a potential new therapeutic option for a rare pediatric disease. Achondroplasia, a genetic disorder affecting bone growth, currently has limited treatment options. The drug's ability to increase annualized height velocity without significant adverse events, especially those associated with FGFR1 inhibition seen in first-generation pan-FGFR inhibitors, suggests a potentially improved safety profile and wider therapeutic window. The FDA's Rare Pediatric Disease Designation and Orphan Drug Designation highlight the unmet medical need and could expedite the drug's development and review process in the U.S. If successful in further trials, lavengratinib could improve the quality of life for children with achondroplasia by addressing a core symptom of the condition. This development also underscores the ongoing advancements in targeted therapies for genetic disorders and the potential for selective inhibitors to offer more effective and safer treatments.
What's Next?
The ABSK061-202 study is ongoing, with participants in higher dose cohorts currently receiving treatment. Six-month efficacy and safety results for the study are anticipated by the end of 2026. These upcoming results will provide further evidence to support the evaluation of lavengratinib's clinical potential in children with achondroplasia. Following the completion of the Phase II trial, Abbisko Therapeutics will likely pursue further clinical development, potentially including Phase III trials, to gather more comprehensive data on the drug's long-term efficacy and safety. Given its Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA, the regulatory pathway for lavengratinib in the U.S. may be streamlined, potentially leading to an accelerated review process if the subsequent trial data are compelling. The company will also need to consider manufacturing and commercialization strategies to make the drug accessible to patients if it receives regulatory approval.
Beyond the Headlines
The development of lavengratinib reflects a broader trend in pharmaceutical research towards highly selective therapies that target specific molecular pathways to minimize off-target effects and improve patient outcomes. For achondroplasia, a condition that impacts not only physical growth but also carries significant social and psychological implications, a safe and effective treatment could have profound effects beyond just increasing height. It could lead to improved mobility, reduced complications, and enhanced overall well-being for affected individuals. The use of an oral mini-tablet formulation, designed for easy administration in children, also highlights a patient-centric approach in drug development, recognizing the unique needs of pediatric populations. This approach could set a precedent for future drug formulations for pediatric rare diseases, emphasizing convenience and compliance. Furthermore, the success of such targeted therapies could encourage more investment and research into other rare genetic disorders, fostering innovation in areas with high unmet medical needs.
